74859-51-1

Basic information

• Product Name: 2-((4-ETHOXYPHENYL)AMINO)-4-NITROBENZOIC ACID
• Synonyms: Benzoic acid, 2-[(4-ethoxyphenyl)aMino]-4-nitro-;N-(4-ETHOXYPHENYL)-4-NITROANTHRANILIC ACID
• CAS NO: 74859-51-1
• Molecular Formula: C₁₅H₁₄N₂O₅
• Molecular Weight: 302.29
• Mol File: 74859-51-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 479.2°C at 760 mmHg
• Flash Point: 243.6°C
• Appearance: /
• Density: 1.371g/cm³
• Vapor Pressure: 5.43E-10mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: 2-((4-ETHOXYPHENYL)AMINO)-4-NITROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((4-ETHOXYPHENYL)AMINO)-4-NITROBENZOIC ACID(74859-51-1)
• EPA Substance Registry System: 2-((4-ETHOXYPHENYL)AMINO)-4-NITROBENZOIC ACID(74859-51-1)

Safety Data

• Hazardous Substances Data: 74859-51-1(Hazardous Substances Data)

Usage

General Description

2-((4-Ethoxyphenyl)amino)-4-nitrobenzoic acid is a chemical compound with the molecular formula C15H13NO5. It is a derivative of benzoic acid, containing a nitro group and an ethoxyphenylamino group. 2-((4-ETHOXYPHENYL)AMINO)-4-NITROBENZOIC ACID has potential use in pharmaceuticals and organic synthesis due to its diverse chemical properties. It is known for its solubility in organic solvents and its ability to act as a dye precursor. Further research on its potential applications and properties is ongoing, making it a subject of interest in various scientific fields.

InChI:InChI=1/C15H14N2O5/c1-2-22-12-6-3-10(4-7-12)16-14-9-11(17(20)21)5-8-13(14)15(18)19/h3-9,16H,2H2,1H3,(H,18,19)

Upstream product

• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 156-43-4 4-Ethoxyaniline 
• 51282-79-2 2-chloro-4-nitrobenzoic acid sodium salt 

Downstream Products

• 20304-69-2 9-chloro-2-ethoxy-6-nitro-acridine 
• 442-16-0 6,9-diamino-2-ethoxyacridine 
• 20304-70-5 9-amino-2-ethoxy-6-nitroacridine 
• 100968-98-7 6-amino-2-ethoxyacridine 

Relevant articles and documents

Development of WNK signaling inhibitors as a new class of antihypertensive drugs

Pseudohypoaldosteronism type II (PHAII) is characterized by hyperkalemia and hypertension despite a normal glomerular filtration rate. Abnormal activation of the signal cascade of with-no-lysine kinase (WNK) with OSR1 (oxidative stress-responsive kinase 1)/SPAK (STE20/SPS1-related proline/alanine-rich kinase) and NCC (NaCl cotransporter) results in characteristic salt-sensitive hypertension. Thus, inhibitors of the WNK-OSR1/SPAK-NCC cascade are candidates for a new class of antihypertensive drugs. In this study, we developed novel inhibitors of this signal cascade from the 9-aminoacridine lead compound 1, one of the hit compounds obtained by screening our chemical library for WNK-SPAK binding inhibitors. Among the synthesized acridine derivatives, several acridine-3-amide and 3-urea derivatives, such as 10 (IC50: 6.9?μM), 13 (IC50: 2.6?μM), and 20 (IC50: 4.8?μM), showed more potent inhibitory activity than the lead compound 1 (IC50: 15.4?μM). Compounds 10 and 20 were confirmed to inhibit phosphorylation of NCC in vivo.

ON THE SYNTHESIS OF ETHOXYPHENYLNITROANTHRANILIC ACID.

-